• Cheng-Yi Hsu, Jui-Ching Chen, Yu-Cheng Tsai, and Tzen-Wen Chen.
• Division of Nephrology, Department of Medicine, Wei-Gong Memorial Hospital, Miaoli, Taiwan, ROC.
• J Chin Med Assoc. 2022 May 1; 85 (5): 566-570.

BackgroundProvision of parenteral or oral iron supplementation can restore iron stores and maintain stable hemoglobin levels in chronic kidney disease (CKD) and hemodialysis (HD) patients. The route for oral or intravenous (IV) administration of iron depends on the acuity of anemia, costs, and patient tolerance. IV iron can restore iron stores rapidly but also carries higher risks for allergy and infection. Oral iron supplementation is limited by high gastrointestinal adverse effects.MethodsWe conducted an open-label trial to study the efficiency of a film-coated iron supplementation tablet, which contains ferrous bisglycinate chelate, vitamin C, and folic acid, in CKD stage 3b to 4 and HD patients.ResultsTwenty-seven HD patients and 20 CKD patients participated this study. After a 16-week intervention, low-dose ferrous bisglycinate chelate improved serum iron concentration (67.8 vs 87.2 mg/dL, p = 0.04) and transferrin saturation (24.7% vs 31.3%, p = 0.03) in stage 3 to 4 CKD patients, restored iron loss, and maintained stable hemoglobin levels in HD patients. No GI upset events were reported.ConclusionFerrous bisglycinate chelate is a well-tolerated oral iron supplementation for CKD and HD patients.Copyright © 2022, the Chinese Medical Association.

27 keywords...

hide…